The Mechanisms of B-cell Acute Lymphoblastic Leukemia Relapsing Following Chimeric Antigen Receptor-T Cell Therapy; the Plausible Future Strategies

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2024 Nov 8

PMID 39514017

Authors

Masoud Karimi-Googheri

Mazaher Gholipourmalekabadi

Zahra Madjd

Ziba Shabani

Zhila Rostami

Mohammad Kazemi Arababadi

Jafar Kiani

Affiliations

Soon will be listed here.

Abstract

Research has demonstrated the high mortality and morbidity associated with B-Acute lymphoblastic lymphoma (B-ALL). Researchers have developed several therapeutic approaches to combat the disorder. Recently, researchers developed chimeric antigen receptors (CARs)-T cells, which recognize antigens independently of major histocompatibility complexes (MHCs) and activate at a higher level with additional persistence. However, relapsing B-ALL has been reported in several cases. This review article was aimed to collecting recent information regarding the mechanisms used by B-ALL-related lymphocytes to escape from CAR-T cells and the plausible resolution projects.

References

Islami F, Sauer A, Miller K, Siegel R, Fedewa S, Jacobs E . Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2017; 68(1):31-54. DOI: 10.3322/caac.21440. View

Miller K, Fidler-Benaoudia M, Keegan T, Hipp H, Jemal A, Siegel R . Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin. 2020; 70(6):443-459. DOI: 10.3322/caac.21637. View

Daban-Lopez P, Fernandez-Martinez N, Petrova D, Rodriguez-Barranco M, Jimenez-Moleon J, Gutierrez J . Epidemiology of human papillomavirus-associated anogenital cancers in Granada: a three-decade population-based study. Front Public Health. 2023; 11:1205170. PMC: 10537955. DOI: 10.3389/fpubh.2023.1205170. View

Zhang H, Lin Z, Cheung F, Cho W, Tang J . Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer. Cochrane Database Syst Rev. 2018; 11:CD010559. PMC: 6517257. DOI: 10.1002/14651858.CD010559.pub2. View

Chalabi M, Verschoor Y, Tan P, Balduzzi S, Van Lent A, Grootscholten C . Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2024; 390(21):1949-1958. DOI: 10.1056/NEJMoa2400634. View

George P, Dasyam N, Giunti G, Mester B, Bauer E, Andrews B . Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). BMJ Open. 2020; 10(2):e034629. PMC: 7044946. DOI: 10.1136/bmjopen-2019-034629. View

Magenau J, Peltier D, Riwes M, Pawarode A, Parkin B, Braun T . Type 1 interferon to prevent leukemia relapse after allogeneic transplantation. Blood Adv. 2021; 5(23):5047-5056. PMC: 9152997. DOI: 10.1182/bloodadvances.2021004908. View

Sanchez-Paulete A, Teijeira A, Cueto F, Garasa S, Perez-Gracia J, Sanchez-Arraez A . Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Ann Oncol. 2017; 28(suppl_12):xii44-xii55. DOI: 10.1093/annonc/mdx237. View

Lee A, Sun L, Mochizuki A, Reynoso J, Orpilla J, Chow F . Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun. 2021; 12(1):6938. PMC: 8626557. DOI: 10.1038/s41467-021-26940-2. View

10.

Rodriguez J . HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation. Oncol Lett. 2017; 14(4):4415-4427. PMC: 5649701. DOI: 10.3892/ol.2017.6784. View

11.

Ravi V, Neidert N, Will P, Joseph K, Maier J, Kuckelhaus J . T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nat Commun. 2022; 13(1):925. PMC: 8854421. DOI: 10.1038/s41467-022-28523-1. View

12.

Wang M, Munoz J, Goy A, Locke F, Jacobson C, Hill B . KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020; 382(14):1331-1342. PMC: 7731441. DOI: 10.1056/NEJMoa1914347. View

13.

Westin J, Oluwole O, Kersten M, Miklos D, Perales M, Ghobadi A . Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023; 389(2):148-157. DOI: 10.1056/NEJMoa2301665. View

14.

Fowler N, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J . Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2021; 28(2):325-332. DOI: 10.1038/s41591-021-01622-0. View

15.

Brudno J, Lam N, Vanasse D, Shen Y, Rose J, Rossi J . Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med. 2020; 26(2):270-280. PMC: 7781235. DOI: 10.1038/s41591-019-0737-3. View

16.

Chong E, Alanio C, Svoboda J, Nasta S, Landsburg D, Lacey S . Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 2021; 139(7):1026-1038. PMC: 9211527. DOI: 10.1182/blood.2021012634. View

17.

Mohanty R, Roy Chowdhury C, Arega S, Sen P, Ganguly P, Ganguly N . CAR T cell therapy: A new era for cancer treatment (Review). Oncol Rep. 2019; 42(6):2183-2195. DOI: 10.3892/or.2019.7335. View

18.

Safarzadeh Kozani P, Naseri A, Mirarefin S, Salem F, Nikbakht M, Evazi Bakhshi S . Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res. 2022; 10(1):24. PMC: 9036779. DOI: 10.1186/s40364-022-00371-7. View

19.

Wang Z, Li N, Feng K, Chen M, Zhang Y, Liu Y . Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021; 18(9):2188-2198. PMC: 8429583. DOI: 10.1038/s41423-021-00749-x. View

20.

June C, Sadelain M . Chimeric Antigen Receptor Therapy. N Engl J Med. 2018; 379(1):64-73. PMC: 7433347. DOI: 10.1056/NEJMra1706169. View